Acetaminophen in Pregnancy: A Population‐Level Drug‐Utilization Study of Prescription‐Based Acetaminophen Use Among Pregnant Women in Denmark From 2001 to 2023
ABSTRACT Acetaminophen is the most used analgetic drug for pain management during pregnancy. A recent academic controversy concerns the safety of acetaminophen during pregnancy related to a potentially increased risk of adverse neurodevelopmental effects. We investigated the population‐level trends...
Uloženo v:
| Vydáno v: | Basic & clinical pharmacology & toxicology Ročník 136; číslo 6; s. e70048 - n/a |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Wiley Subscription Services, Inc
01.06.2025
John Wiley and Sons Inc |
| Témata: | |
| ISSN: | 1742-7835, 1742-7843, 1742-7843 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | ABSTRACT
Acetaminophen is the most used analgetic drug for pain management during pregnancy. A recent academic controversy concerns the safety of acetaminophen during pregnancy related to a potentially increased risk of adverse neurodevelopmental effects. We investigated the population‐level trends in prescription‐based use of acetaminophen among pregnant women in Denmark between 2001 and 2023. Prescription‐based sals of acetaminophen among pregnant women and comparison groups were retrieved from ‘eSundhed’, a publicly available dataset curated by the Danish Health Authorities. The number of prescription‐based drug users per 1000 pregnant women increased slightly from 2001 to 2012 (3.9 to 6.5 per 1000) and 2015 to 2023 (52 to 76 per 1000), interrupted by a drastic increase in 2013/2014. Acetaminophen use among pregnant women (2023: 76 per 1000) was lower than in women in an age‐matched comparison group (137 per 1000) and in women 12–3 months prior to pregnancy (124 per 1000). Time trends did not notably differ between age groups or comparison groups. Prescription‐based acetaminophen sales among pregnant women increased by 50% from 2015 to 2023. A general shift in the prescription pattern towards a substantial increase in prescription‐based exposure was observed following legislation changes in 2013, restricting sales of large packages to prescription. |
|---|---|
| Bibliografie: | The authors received no specific funding for this work. Funding ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding: The authors received no specific funding for this work. |
| ISSN: | 1742-7835 1742-7843 1742-7843 |
| DOI: | 10.1111/bcpt.70048 |